Optical Biosensing of Bacteria and Bacterial Communities

Hu, Jiayun; Bohn, Paul W.

doi:10.1007/s41664-017-0002-z

Cited by 21 publications

(14 citation statements)

References 115 publications

(162 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combination of miniature MS system and POCT should meet several criteria including easy to operate, low cost, portable size, and high reliability. Commercial Mini 12, a rectilinear ion trap (tandem MS capability to MS) equipped with a PS ambient ion source, was used for direct quantitative detection of amitriptyline spiked whole blood . The reported LOD was 7.5 ng mL −1 with a coefficient of variance (CV) lower than 10%, which illustrated the feasibility and robustness of this system.…”

Section: Further Perspectivesmentioning

confidence: 98%

“…Ultrasensitive and selective detection of cancer biomarkers at early stages enables effective therapeutic treatment and intervention that can significantly increase the cure rate and reduce patients' sufferings, economic cost of treatment, and cancer mortality. In the past few decades, great efforts and substantial progress have been made in this field, and various methods, such as colorimetric screening, enzyme‐linked immunosorbent assay (ELISA), fluorescence, polymerase chain reaction (PCR), and electrochemical assays, have been extensively performed in clinical laboratory tests. Although with efficiency and robustness, the majority of these methods still lack sufficient accuracy, sensitivity, and specificity for clinical diagnostic applications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mass Spectrometry Methods for In Situ Analysis of Clinical Biomolecules

Liu

et al. 2019

Small Methods

View full text Add to dashboard Cite

past few decades, great efforts and substantial progress have been made in this field, and various methods, such as colorimetric screening, [3] enzyme-linked immunosorbent assay (ELISA), [4] fluorescence, [5] polymerase chain reaction (PCR), [6] and electrochemical assays, [7] have been extensively performed in clinical laboratory tests. Although with efficiency and robustness, the majority of these methods still lack sufficient accuracy, sensitivity, and specificity for clinical diagnostic applications.The inevitable complexity and challenges of clinical biomolecules detection have encouraged researchers to continuously devote great effort to the development of new methods with accuracy, rapidity, and simplicity. Relying on its high throughput and accuracy, great sensitivity and versatility, reliable qualitative and quantitative ability, and multiplexed detection capability, mass spectrometry (MS) is exceptionally suitable for clinical analysis and blooming in modern healthcare industry in recent years. [8][9][10] MS coupled to liquid chromatography (LC) and gas chromatography (GC) is regarded as gold standards for quantitative analysis of various compounds and have been conventionally used in clinical applications such as toxicology, [11] therapeutic drug monitoring, [12] inborn error of metabolism (IEM), [13] and steroid hormone testing [14] for decades. IEMs cause high morbidity and mortality in children, and the utilization of GC-MS and LC-MS expands newborn IEMs screening from single-screening assays to simultaneously screening of various analytes (e.g., amino acids, organic acids, carnitine, and acylcarnitine) in a single run using one sample from the patient. Some reviews have summarized a number of excellent works about applications of GC-MS and LC-MS in clinical chemistry. [15,16] These hyphenated MS methods provide accurate quantification data and abundant information of clinical biomolecules, which facilitates biological behavior understanding, biomarker discovery, and prognosis evaluation. However, in most cases, these methods are conducted by using lysis of cells or tissues, which fail to provide real-time information and spatial distribution of biomolecules in their native states. On the other hand, tedious sample pretreatment (separation, purification, and redissolution) is inevitable. These series of labor intensive and time-consuming procedures may cause unpredictable sample loss and undervaluation of biomolecules. Therefore, chromatography-based MS methods are limited to achieve high-throughput, in situ, and visual clinical applications. The development of emerging Due to the significant role of clinical biomolecules in mediating biological activities and disease progressions, in situ analysis provides a great opportunity for understanding the molecular mechanisms of biological functions, facilitating medical diagnosis, clinical treatment, and prognosis. Among all the analysis methods, mass spectrometry (MS) methodologies exhibit unique features that make them exceptionally suitable for clinica...

show abstract

Section: Further Perspectivesmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Mass Spectrometry Methods for In Situ Analysis of Clinical Biomolecules

Liu

et al. 2019

Small Methods

View full text Add to dashboard Cite

show abstract

“…Some other concerns with the use of antibodies include the variation from batch-to-batch during production, temperature and pH instabilities, potential affinity loss due to mutation of bacterial receptors and ethical issues with using animals to harvest antibodies (Hu & Bohn, 2017;Peterson & Peavey, 1998).…”

Section: Antibodiesmentioning

confidence: 99%

“…They can be produced in large amounts at relatively low cost, and they are stable under a wide range of conditions. However, it is still possible to lose the affinity for the target over time (Hu & Bohn, 2017), and the number of available aptamers is still substantially smaller than that of antibodies.…”

Section: Non-antibody Receptorsmentioning

confidence: 99%

The future of microbiome analysis: Biosensor methods for big data collection and clinical diagnostics

Akarapipad

Yoon

2020

Med Devices & Sens

View full text Add to dashboard Cite

Worldwide interest in the human microbiome is rapidly expanding, as the microbiome is a potential key to understanding human health and improving diagnostic and treatment strategies. A wide array of microorganisms, including bacteria, archaea, unicellular/multicellular eukaryotes (i.e. fungi and helminths) and viruses, colonize on the human body. Their activity and interactions with each other impact their host (Rowan-Nash, Korry, Mylonakis, & Belenky, 2019). Although sometimes used interchangeably, the word 'microbiota' refers to the collective community of microorganisms residing in a particular environment (such as a region of the body), whereas the word 'microbiome' refers to the entirety of this community's genetic information (Allaband et al., 2019; Kuczynski et al., 2012). The different regions of the human body contain various combinations of microbes that could provide information not only about infectious diseases at specific sites, but also about the potential health conditions of a person (Mimee et al., 2018). It is remarkable to consider that, according to recently revised estimates, the human body houses approximately as many bacteria (the most abundant member of the microbiota) as human cells, with bacteria comprising 0.3% of total body mass (Sender, Fuchs, & Milo, 2016). According to the

show abstract

“…8 Because it is desirable to optimize detection speed, sensitivity, selectivity, and cost for bacterial diagnostics, research into bacterial detection continues to be of substantial interest. 5,9–11 …”

mentioning

confidence: 99%

Whole-Cell Pseudomonas aeruginosa Localized Surface Plasmon Resonance Aptasensor

Bohn

2018

Anal. Chem.

Self Cite

View full text Add to dashboard Cite

The detection of whole-cell Pseudomonas aeruginosa presents an intriguing challenge with direct applications in health care and the prevention of nosocomial infection. To address this problem, a localized surface plasmon resonance (LSPR) based sensing platform was developed to detect whole-cell Pseudomonas aeruginosa strain PAO1 using a surface-confined aptamer as an affinity reagent. Nanosphere lithography (NSL) was used to fabricate a sensor surface containing a hexagonal array of Au nanotriangles. The sensor surface was subsequently modified with biotinylated polyethylene glycol (Bt-PEG) thiol/PEG thiol (1:3), neutravidin, and biotinylated aptamer in a sandwich format. The 1:3 (v/v) ratio of Bt-PEG thiol/PEG thiol was specifically chosen to maximize PAO1 binding while minimizing nonspecific adsorption and steric hindrance. In contrast to prior whole-cell LSPR work, the LSPR wavelength shift was shown to be linearly related to bacterial concentration over the range of 10–103 cfu mL−1. This LSPR sensing platform is rapid (~3 h for detection), sensitive (down to the level of a single bacterium), selective for detection of Pseudomonas strain PAO1 over other strains, and exhibits a clinically relevant dynamic range and excellent shelf life (≥2 months) when stored at ambient conditions. This versatile LSPR sensing platform should be extendable to a wide range of supermolecular analytes, including both bacteria and viruses, by switching affinity reagents, and it has potential to be used in point-of-care and field-based applications.

show abstract

Optical Biosensing of Bacteria and Bacterial Communities

Cited by 21 publications

References 115 publications

Mass Spectrometry Methods for In Situ Analysis of Clinical Biomolecules

Mass Spectrometry Methods for In Situ Analysis of Clinical Biomolecules

The future of microbiome analysis: Biosensor methods for big data collection and clinical diagnostics

Whole-Cell Pseudomonas aeruginosa Localized Surface Plasmon Resonance Aptasensor

Contact Info

Product

Resources

About